Next Article in Journal
Improving Uptake of Postnatal Checking of Blood Glucose in Women Who Had Gestational Diabetes Mellitus in Universal Healthcare Settings: A Systematic Review
Previous Article in Journal
Innate Immune Responses and Viral-Induced Neurologic Disease
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2019, 8(1), 6; https://doi.org/10.3390/jcm8010006

Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections

1
Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
2
Amity Institute of Virology and Immunology, Amity University, Noida 201303, India
3
Sanofi Pasteur, Asia and JPAC Region, Singapore 257856, Singapore
4
Regional Centre for Animal Influenza, National Veterinary Research Institute, Vom 930010, Nigeria
5
Department of Respiratory Virology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110007, India
*
Authors to whom correspondence should be addressed.
Received: 26 November 2018 / Revised: 18 December 2018 / Accepted: 19 December 2018 / Published: 20 December 2018
(This article belongs to the Section Microbiology & Parasitology)
Full-Text   |   PDF [1394 KB, uploaded 20 December 2018]   |  

Abstract

Several viruses cause pulmonary infections due to their shared tropism with cells of the respiratory tract. These respiratory problems due to viral infection become a public health concern due to rapid transmission through air/aerosols or via direct-indirect contact with infected persons. In addition, the cross-species transmission causes alterations to viral genetic makeup thereby increasing the risk of emergence of pathogens with new and more potent infectivity. With the introduction of effective nucleic acid-based technologies, post translational gene silencing (PTGS) is being increasingly used to silence viral gene targets and has shown promising approach towards management of many viral infections. Since several host factors are also utilized by these viruses during various stages of infection, silencing these host factors can also serve as promising therapeutic tool. Several nucleic acid-based technologies such as short interfering RNAs (siRNA), antisense oligonucleotides, aptamers, deoxyribozymes (DNAzymes), and ribozymes have been studied and used against management of respiratory viruses. These therapeutic nucleic acids can be efficiently delivered through the airways. Studies have also shown efficacy of gene therapy in clinical trials against respiratory syncytial virus (RSV) as well as models of respiratory diseases including severe acute respiratory syndrome (SARS), measles and influenza. In this review, we have summarized some of the recent advancements made in the area of nucleic acid based therapeutics and highlighted the emerging roles of nucleic acids in the management of some of the severe respiratory viral infections. We have also focused on the methods of their delivery and associated challenges. View Full-Text
Keywords: nucleic acid therapy; siRNA; ribozyme; aptamers; DNAzyme; influenza virus; RSV; SARS-CoV; adenovirus; antiviral drugs nucleic acid therapy; siRNA; ribozyme; aptamers; DNAzyme; influenza virus; RSV; SARS-CoV; adenovirus; antiviral drugs
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Asha, K.; Kumar, P.; Sanicas, M.; Meseko, C.A.; Khanna, M.; Kumar, B. Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections. J. Clin. Med. 2019, 8, 6.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top